Renal Cell Cancer

• ESMO Preceptorship on Hereditary Cancer Genetics Lugano April 2019
• Moving into the future understanding the present
• Participant Clinical Case Discussion: Genetic Considerations in Kidney Cancer
• Systemic treatment of advanced renal cancer
• Metastatic renal cancer: Evidence-based treatment
• ESMO Summit Africa 2019
• ESMO E-Learning: Advances in Systemic Treatment of Advanced/Metastatic Renal Cell Carcinoma
• Renal Cell Carcinoma: ESMO Clinical Practice Guidelines
• Expert Video Report on Renal Cell Carcinoma
• Practice changing studies in Bladder and Kidney Cancers in 2018
• Case Presentation in Bladder or Kidney Cancers
• Standards of Care and development of new targets in Bladder and Kidney Cancers
• ESMO E-Learning: Present and Emerging Treatment Options in HER2/neu Overexpressing Metastatic Breast Cancer
• Advanced Urinary Cancer (Renal and Bladder)
• SURTIME Indicates Role For Sunitinib Before Cytoreductive Nephrectomy In mRCC Patients
• ESMO Preceptorship on Metastatic Bladder and Kidney Cancer Zurich November 2018
• Participants Clinical Case Discussion: Systemic Therapy in Metastatic RCC
• Debate: No, Immunotherapy is not the Standard First-line Therapy for mRCC
• Debate: Yes, Immunotherapy is the Standard First-line Therapy for mRCC
• Participants Clinical Case Discussion: Case of Metastatic Clear Renal Cancer with Treatment with More that 5 Agents
• mRCC: Immunotherapy
• mRCC: Anti-angiogenic Therapy
• Participants Clinical Case Discussion: Metastatic Kidney Cancer
• Participants Clinical Case Discussion: Renal Cell Carcinoma with Hepatic, Pulmonary and Brain Metastases
• Radiotherapy in Metastatic Urothelial Cancer and RCC

• « Previous
• 1
• 2
• ...
• 17
• Next »